Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 16, 2009 - Issue 4
96
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Withdrawn: Severe ataxia with neuropathy in hereditary gelsolin amyloidosis

, , , , , , & show all
Page 246 | Published online: 20 Oct 2009

References

  • Meretoja J. Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes, and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1969;14:314–32.
  • Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 1998;51:55–66.
  • Stewart HS, Parveen R, Ridgway AE, Bonshek R, Black GC. Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family. Brit J Ophthalmol 2000;844:390–394.
  • Conceicao I, Sales-Luis ML, De Carvalho M, Evangelista T, Fernandes R, Paunio T, Kangas H, Coutinho P, Neves C, Saraiva MJ. Gelsolin-related familial amyloidosis, Finnish type, in a Portuguese family: Clinical and neurophysiological studies. Muscle Nerve 2003;28:715–721.
  • Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B. Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 1990;172:1865–1867.
  • de la Chapelle A, Tolvanen R, Boysen G, Santavy J, Bleeker-Wagemakers L, Maury CP, Kere J. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 1992;22:157–160.
  • Paunio T, Kiuru S, Hongell V, Mustonen E, Syvanen AC, Bengstrom M, Palo J, Peltonen L. Solid-phase minisequencing test reveals Asp187Asn (G654A) mutation of gelsolin in all affected individuals with Finnish type of familial amyloidosis. Genomics 1992;13:237–239.
  • Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999;11:103–108.
  • Paunio T, Kangas H, Kalkkinen N, Haltia M, Palo J, Peltonen L. Toward understanding the pathogenic mechanisms in gelsolin-related amyloidosis: In vitro expression reveals an abnormal gelsolin fragment. Hum Mol Genet 1994;3:2223–2229.
  • Kangas H, Paunio T, Kalkkinen N, Jalanko A, Peltonen L. In vitro expression analysis shows that the secretory form of gelsolin is the sole source of amyloid in gelsolin-related amyloidosis. Hum Mol Genet 1996;5:1237–1243.
  • Chen CD, Huff ME, Matteson J, Page L, Phillips R, Kelly JW, Balch WE. Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 2001;20:6277–6287.
  • Page LJ, Suk JY, Huff ME, Lim HJ, Venable J, Yates J, Kelly JW, Balch WE. Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 2005;24:4124–4132.
  • Kiuru S, Salonen O, Haltia M. Gelsolin-related spinal and cerebral amyloid angiopathy. Ann Neurol 1999;45:305–311.
  • Kiuru-Enari S, Keski-Oja J, Haltia M. Cutis laxa in hereditary gelsolin amyloidosis. Brit J Dermatol 2005;152:250–257.
  • Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JW. Heparin accelerates gelsolin amyloidogenesis. Biochemistry-US 2006;45:2234–2242.
  • Weeds AG, Gooch J, McLaughlin P, Maury CP. Variant plasma gelsolin responsible for familial amyloidosis (Finnish type) has defective actin severing activity. FEBS Lett 1993;335:119–123.
  • Robinson RC, Choe S, Burtnick LD. The disintegration of a molecule: The role of gelsolin in FAF, familial amyloidosis Finnish type). P Natl Acad Sci USA 2001;98:2117–2118.
  • Westberg JA, Zhang KZ, Andersson LC. Regulation of neural differentiation by normal and mutant (G654A, amyloidogenic) gelsolin. FASEB J 1999;13:1621–1626.
  • Kiuru S, Javela K, Somer H, Kekomaki R. Altered platelet shape change in hereditary gelsolin Asp187Asn-related amyloidosis. Thromb Haemostasis 2000;83:491–495.
  • Rosenberg ME, Tervo TM, Gallar J, Acosta MC, Muller LJ, Moilanen JA, Tarkkanen AH, Vesaluoma MH. Corneal morphology and sensitivity in lattice dystrophy type II (familial amyloidosis, Finnish type). Invest Ophth Vis Sci 2001;42:634–641.
  • Kiuru-Enari S, Somer H, Seppalainen AM, Notkola IL, Haltia M. Neuromuscular pathology in hereditary gelsolin amyloidosis. J Neuropathol Exp Neurol 2002;61:565–571.
  • Klaus E, Freyberger E, Kavka G, Vodicka F. Familial occurrence of a bulbar paralytic form of amyotropic lateral sclerosis with reticular corneal dystrophy and cutis hyperelastica in 3 sisters. Psychiatr Neurol (Basel) 1959;138:79–97.
  • Akiya S, Nishio Y, Ibi K, Uozumi H, Takahashi H, Hamada T, Onishi A, Ishiguchi H, Hoshii Y, Nakazato M. Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV. Ophthalmology 1996;103:1106–1110.
  • Lauria G, Pareyson D, Grisoli M, Sghirlanzoni A. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies. Ann Neurol 2000 Jan;47:104–109.
  • Metzler JP, Fleckenstein JL, White CL, 3rd, Haller RG, Frenkel EP, Greenlee RG, Jr. MRI evaluation of amyloid myopathy. Skeletal Radiol 1992;21:463–465.
  • Rintala AE, Alanko A, Makinen J, Nordstrom R, Salo H. Primary hereditary systemic amyloidosis (Meretoja's syndrome): Clinical features and treatment by plastic surgery. Scand J Plast Recons 1988;22:141–145.
  • Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: An underdiagnosed entity. Ann Neurol 1998;43:719–728.
  • Delcey V, Hachulla E, Michon-Pasturel U, Queyrel V, Hatron PY, Boutry N, Lemaitre V, Vanhille P, Serratrice J, Disdier P, Juhan V, Devulder B, Thevenon A. Camptocormia: a sign of axial myopathy. Report of 7 cases. Rev Med Interne 2002;23:144–154.
  • Paunio T, Kangas H, Heinonen O, Buc-Caron MH, Robert JJ, Kaasinen S, Julkunen I, Mallet J, Peltonen L. Cells of the neuronal lineage play a major role in the generation of amyloid precursor fragments in gelsolin-related amyloidosis. J Biol Chem 1998 Jun;273:16319–16324.
  • Makishita H, Ikeda S, Yazaki M, Yamane M, Yumoto K, Maury C-J, Yanagiswa N. Postmortem pathological findings in a Japanese patient with familia amyloidosis, Finnish type (FAF). Amyloid 1996;3:134–139.
  • Soto C, Castano EM, Prelli F, Kumar RA, Baumann M. Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, gelsolin and AA amyloids. FEBS Lett 1995;371:110–114.
  • Rostagno A, Revesz T, Lashley T, Tomidokoro Y, Magnotti L, Braendgaard H, Plant G, Bojsen-Moller M, Holton J, Frangione B, Ghiso J. Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem 2002;277:49782–49790.
  • Tanskanen M, Lindsberg PJ, Tienari PJ, Polvikoski T, Sulkava R, Verkkoniemi A, Rastas S, Paetau A, Kiuru-Enari S. Cerebral amyloid angiopathy in a 95+ cohort: Complement activation and apolipoprotein E (APOE) genotype. Neuropathol Appl Neurobiol 2005;31:589–599.
  • Nylander PO, Beckman L, Holmgren G, Steen L. Association of C3 and C4A complement types with familial amyloidotic polyneuropathy. Hum Hered 1990;40:272–277.
  • Brady ST, Lasek RJ, Allen RD, Yin HL, Stossel TP. Gelsolin inhibition of fast axonal transport indicates a requirement for actin microfilaments. Nature 1984;310:56–58.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.